Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?

Letter/Communication

S Gamerman, A M Singh, M Makhija and A Sharathkumar

Haemophilia : the official journal of the World Federation of Hemophilia, Vol.19(6), pp.e382-e385

11/2013

DOI: 10.1111/hae.12238

PMID: 23992223

View Online

Letter to the editor

Recombinant Proteins - therapeutic use

Factor IX - analysis

Humans

Hemophilia B - blood

Intracranial Hemorrhages - etiology

Antibodies, Monoclonal, Murine-Derived - metabolism

Half-Life

Rituximab

Infant

Male

Intracranial Hemorrhages - drug therapy

Blood Coagulation Factor Inhibitors - antagonists & inhibitors

Factor VIIa - therapeutic use

Blood Coagulation Factor Inhibitors - blood

Hemophilia B - drug therapy

Coagulants - therapeutic use

Hemophilia B - complications

Blood Coagulation Factors - therapeutic use

Immunologic Factors - metabolism

Desensitization, Immunologic

Antibodies, Monoclonal, Murine-Derived - therapeutic use

Immunologic Factors - therapeutic use

Title: Subtitle: Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?
Creators: S Gamerman - Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL
A M Singh
M Makhija
A Sharathkumar
Resource Type: Letter/Communication
Publication Details: Haemophilia : the official journal of the World Federation of Hemophilia, Vol.19(6), pp.e382-e385
DOI: 10.1111/hae.12238
PMID: 23992223
ISSN: 1351-8216
eISSN: 1365-2516
Language: English
Date published: 11/2013
Academic Unit: Stead Family Department of Pediatrics; Hematology/Oncology
Record Identifier: 9984093234902771

21 Record Views